Antengene Corporation Limited (HK:6996) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Antengene Corporation Limited has announced that its drug XPOVIO, used to treat relapsed or refractory diffuse large B-cell lymphoma, will be included in China’s 2024 National Reimbursement Drug List. This inclusion marks a significant milestone for Antengene, potentially enhancing its market presence and financial performance. Investors and shareholders may find this development promising as it could lead to increased adoption and sales of XPOVIO in the region.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
